Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

Lenacapavir, trialed in Uganda, offers 100% protection but will it reach those who need it most? Kampala, Uganda | RONALD ...

A landmark breakthrough in HIV prevention received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had started ...

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has announced that it has signed an access agreement with Pharmaceutical Company Gilead Sciences to procure lenacapavir, a ...